REG - Allergy Therapeutics - Director Dealings

Allergy TherapeuticsAnnouncement

11/11/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211111:nRSK0193Sa&default-theme=true

RNS Number : 0193S  Allergy Therapeutics PLC  11 November 2021

 

 

Allergy Therapeutics plc

 

("Allergy Therapeutics" or the "Company")

 

Director Dealings

 

11 November 2021 - Allergy Therapeutics (AIM: AGY), the fully integrated
specialty pharmaceutical group specialising in allergy vaccines, announces
that Peter Jensen, Non-Executive Chairman, has purchased 30,000 ordinary
shares of 0.1 pence each in the capital of the Company ("Ordinary Shares") at
a price of 36 pence per Ordinary Share. Following the transaction, the total
beneficial interest of Peter Jensen is 300,000 Ordinary Shares, representing
0.05% of the of the issued share capital of the Company to which voting rights
are attached.

 

For further information, please contact:

 

Allergy Therapeutics

+44 (0) 1903 845 820

Manuel Llobet, Chief Executive Officer

Nick Wykeman, Chief Financial Officer

 

Panmure Gordon

+44 (0) 20 7886 2500

Freddy Crossley, Emma Earl, Corporate Finance

Rupert Dearden, Corporate Broking

 

Consilium Strategic Communications

+44 20 3709 5700

Mary-Jane Elliott, David Daley, Davide Salvi, Alex Gunter

allergytherapeutics@consilium-comms.com
(mailto:allergytherapeutics@consilium-comms.com)

 

 

Notes for editors:

 

About Allergy Therapeutics

 

Allergy Therapeutics is an international commercial biotechnology group
focussed on the treatment and diagnosis of allergic disorders, including
immunotherapy vaccines that have the potential to cure disease. The Group
sells proprietary and third party products from its subsidiaries in nine major
European countries and via distribution agreements in an additional fourteen
countries. Its broad pipeline of products in clinical development include
vaccines for grass, tree and house dust mite, and peanut allergy vaccine in
pre-clinical development. Adjuvant systems to boost performance of vaccines
outside allergy are also in development.

 

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is
headquartered in Worthing, UK with more than 11,000m2 of state-of-the-art
MHRA-approved manufacturing facilities and laboratories. The Group, which has
achieved 10% compound annual growth since formation, employs c.500 employees
and is listed on the London Stock Exchange (AIM:AGY). For more information,
please see www.allergytherapeutics.com (http://www.allergytherapeutics.com) .

 

 

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and/or persons closely associated with them:

 

 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name                                                         Peter Jensen

 2   Reason for the notification
 a)  Position/status                                              Non-Executive Chairman, Director

 b)  Initial notification/Amendment                               Initial Notification

 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         Allergy Therapeutics plc
 b)  LEI                                                          213800PQ7AHK7KGVOE23
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  0.1p ordinary shares

     Identification code

                                                                  GB00B02LCQ05
 b)  Nature of the transaction                                    Purchase of Ordinary Shares

 c)  Price(s) and volume(s)                                       Price(s) per Ordinary Share  Volume(s)

                                                            36 pence                     30,000

 d)  Aggregated information

                                                                  N/A

 e)  Date of the transaction                                      10 November 2021

 f)  Place of the transaction                                     London Stock Exchange - AIM

d)

Aggregated information

 

 

N/A

 

e)

Date of the transaction

 

10 November 2021

f)

Place of the transaction

 

 

London Stock Exchange - AIM

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHMZMMMMGZGMZZ